Business

Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer Meeting the Primary Endpoint

Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer Meeting the Primary Endpoint

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AFebruary 23, 20264/news/announcement-on-voluntary-disclosure-of-interim-analysis-of-the-phase-iii-clinical-trial-of-iza-bren-egfrher3-bispecific-adc-for-the-treatment-of-locally-advanced-or-metastatic-triple-negative-breast-cancer-meeting-the-primary-endpoint
Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer Meeting the Primary Endpoint

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer Meeting the Primary Endpoint The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A